Dialysis patients treated with Epoetin α show improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trial

Hemodialysis International

Volumn 15, Issue 1, 2011, Pages 87-94

  Muirhead, Norman ^a   Keown, Paul A ^b   Churchill, David N ^c   Poulin Costello, Melanie ^c   Gantotti, Sandeep ^c   Lei, Lei ^d   Gitlin, Matthew ^d   Mayne, Tracy J ^e  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Amgen Canada Inc   (Canada)

^d AMGEN INC   (United States)

^e DAVITA INC   (United States)

Author keywords

Anemia; Chronic kidney disease; Dialysis; Epoetin ; Erythropoiesis stimulating agents; Health related quality of life

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION REACTION; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG FATALITY; DRUG WITHDRAWAL; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHYSICAL CAPACITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; SUBARACHNOID HEMORRHAGE; ADOLESCENT; CANADA; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HEMODIALYSIS; MIDDLE AGED; PROCEDURES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CANADA; DOUBLE-BLIND METHOD; EPOETIN ALFA; ERYTHROPOIETIN; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RENAL DIALYSIS; YOUNG ADULT;

EID: 79251541755     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2010.00508.x     Document Type: Article

References (24)

1. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339:584-590.
2. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355:2085-2098.
3. US Renal Data System. USRDS 2008 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2008.
4. Crowley JP, Nealey TA, Metzger J, Pono L, Chazan JA. Transfusion and long-term hemodialysis. Arch Intern Med. 1987; 147:1925-1928.
5. Goodnough LT, Strasburg D, Riddell JIV, Verbrugge D, Wish J. Has recombinant human erythropoietin therapy minimized red-cell transfusions in hemodialysis patients? Clin Nephrol. 1994; 41:303-307.
6. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989; 111:992-1000.
7. Ibrahim HN, Ishani A, Foley RN, Guo H, Liu J, Collins AJ. Temporal trends in red blood transfusion among US dialysis patients, 1992-2005. Am J Kidney Dis. 2008; 52:1115-1121.
8. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative multicenter EPO clinical trial group. JAMA. 1990; 263:825-830.
9. Lundin AP, Akerman MJ, Chesler RM, et al. Exercise in hemodialysis patients after treatment with recombinant human erythropoietin. Nephron. 1991; 58:315-319.
10. FDA. US Department of Health and Human Services Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims, 2009. Available from (accessed date: March 5, 2010).
11. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990; 300:573-578.
12. Naughton J, Sevelius G, Balke B. Physiological responses of normal and pathological subjects to a modified work capacity test. J Sports Med Phys Fitness. 1963; 44:201-207.
13. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: A new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985; 132:919-923.
14. Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of life in clinical trials. Can Med Assoc J. 1986; 134:889-895.
15. Laupacis A, Muirhead N, Keown P, Wong C. A disease-specific questionnaire for assessing quality of life in patients on hemodialysis. Nephron. 1992; 60:302-306.
16. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: Development and final revision of a health status measure. Med Care. 1981; 19:787-805.
17. Keown PA, Churchill DN, Poulin-Costello M, et al. Dialysis patients treated with Epoetin alfa show imporved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int. 2010; 14:168-173.
18. Cleland JG, Dargie HJ, Hodsman GP, et al. Captopril in heart failure A double blind controlled trial. Br Heart J. 1984; 52:530-535.
19. Braumann KM, Nonnast-Daniel B, Boning D, Bocker A, Frei U. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron. 1991; 58:129-134.
20. Barany P, Pettersson E, Konarski-Svensson JK. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin. Nephrol Dial Transplant. 1993; 8:426-432.
21. Johansen KL, Finkelstein FO, Revicki DA, Gitlin M, Evans C, Mayne TJ. Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis. 2010; 55:535-548.
22. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361:2019-2032.
23. Pfeffer MA, Burdmann EA, Chen CY, et al. Baseline characteristics in the trial to reduce cardiovascular events with Aranesp therapy (TREAT). Am J Kidney Dis. 2009; 54:59-69.
24. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009.